| abstract |
This invention relates to methods for treating, preventing and/or managing cancer in a subject including enhacing the efficacy of a Vascular Disrupting Agent (e.g., a combretastatin or derivative thereof) by administering to the subject a Chemokine Receptor Angtagonist (e.g., a CXCR4 antagonist) or Chemokine Antagonist (e.g., a SDF- 1 antagonist) sequentially or simultaneously in combination with said Vascular Disrupting Agent. |